Hematologic Diseases: Clinical Trials

885 trials for Hematologic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

885 terminated. 885 Phase 1, 328 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1885Terminated 885
Phase 2328Terminated 328

Follow Hematologic Diseases: new trials by email Literature Review of Hematologic Diseases trials Research Report on Hematologic Diseases

Trials (filtered) newest first · largest first

All 885 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
Antigen-specific T cells CAR-T/CTL and DCvac - T-Cell Acute Lymphoblastic Leukemia
Phase 1TerminatedShenzhen Geno-Immune Medical Institute102026-06-012026-11-03
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Pociredir - Sickle Cell Disease
Phase 1TerminatedFulcrum Therapeutics132025-12-132026-06-18
Multiple CAR-T Cell Therapy Targeting AML
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute102025-08-012026-11-02
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
4SCAR19 and 4SCAR22, 4SCAR19 and 4SCAR38, 4SCAR19 and 4SCAR20 - B-cell Malignancies
Phase 1 / Phase 2TerminatedShenzhen Geno-Immune Medical Institute1002025-08-012026-10-30
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
Phase 1TerminatedPfizer62025-05-082026-05-08
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
YTS109 cell injection - Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
Phase 1TerminatedChina Immunotech (Beijing) Biotechnology Co., Ltd.22025-04-162026-10-14
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
CD19 t-haNK - B-ALL, Leukemia
Phase 1TerminatedImmunityBio, Inc.42025-04-112026-08-19
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
S227928, Venetoclax - Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML
Phase 1 / Phase 2TerminatedServier Bio-Innovation LLC132025-02-252026-03-30
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion Dose - AML, Adult Recurrent, ALL, Recurrent, Adult
Phase 1 / Phase 2TerminatedBlueSphere Bio, Inc22025-02-042026-09-10
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
BL-M11D1 - Relapsed/Refractory Acute Myeloid Leukemia
Phase 1TerminatedSystImmune Inc.522024-12-192026-09-24
ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1TerminatedUniversity of Washington12024-12-182025-07-29
A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
AUR104 - Select Relapsed/Refractory Lymphoid Malignancies
Phase 1TerminatedAurigene Discovery Technologies Limited92024-12-122026-04-17
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
BE-101 - Hemophilia B, Hemophilia B, Moderately Severe or Severe
Phase 1 / Phase 2TerminatedBe Biopharma52024-12-042026-06-15
Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)
Venetoclax, Azacitidine, Donor Lymphocyte Infusion - Acute Myeloid Leukemia
Phase 1TerminatedAntonio M Jimenez Jimenez22024-12-042026-07-13
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
Luveltamab tazevibulin - Acute Myeloid Leukemia (AML)
Phase 1 / Phase 2TerminatedSutro Biopharma, Inc.12024-12-042026-10-13
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Biopsy, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1TerminatedRoswell Park Cancer Institute12024-11-262025-08-03
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
NMS-03597812 - Relapsed/Refractory Acute Myeloid Leukemia
Phase 1TerminatedNerviano Medical Sciences232024-10-162026-11-19
Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]
NP137, Azacitidine Injection, Venetoclax - Acute Myeloid Leukemia Refractory
Phase 1 / Phase 2TerminatedCentre Leon Berard12024-09-112025-02-20
Study of Tazemetostat in Lymphoid Malignancies
Tazemetostat - T-cell Lymphoma
Phase 1TerminatedUniversity of Alabama at Birmingham62024-09-052026-04-17
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
SAR443579, venetoclax, azacitidine - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedSanofi72024-08-132026-10-19

Showing 20 of 885. Sign in to see all of them.

Narrower conditions

Leukemia, Myeloid, Acute (290)  ·  Multiple Myeloma (213)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (154)  ·  Leukemia (145)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (132)  ·  Myelodysplastic Syndromes (131)  ·  Recurrence (109)  ·  Lymphoma, Non-Hodgkin (96)  ·  Lymphoma (85)  ·  Lymphoma, Large B-Cell, Diffuse (68)  ·  Lymphoma, Mantle-Cell (63)  ·  Lymphoma, Follicular (59)  ·  Hematologic Neoplasms (58)  ·  Neoplasms (57)  ·  Burkitt Lymphoma (51)

Broader conditions

Hemic and Lymphatic Diseases (885)  ·  Neoplasms by Histologic Type (724)  ·  Neoplasms (706)  ·  Immune System Diseases (497)  ·  Immunoproliferative Disorders (469)  ·  Lymphoproliferative Disorders (463)  ·  Leukemia (400)  ·  Pathological Conditions, Signs and Symptoms (344)  ·  Pathologic Processes (340)  ·  Disease Attributes (321)  ·  Leukemia, Myeloid (319)  ·  Lymphatic Diseases (314)  ·  Hemorrhagic Disorders (272)  ·  Cardiovascular Diseases (247)

Interventions

Dexamethasone (68)  ·  Cyclophosphamide (63)  ·  Cytarabine (58)  ·  fludarabine (56)  ·  Azacitidine (54)  ·  venetoclax (43)  ·  Rituximab (38)  ·  Lenalidomide (37)  ·  Bortezomib (33)  ·  fludarabine phosphate (30)  ·  Calcium Dobesilate (29)  ·  Filgrastim (23)  ·  Decitabine (18)  ·  Melphalan (17)  ·  pomalidomide (17)

Sponsors

M.D. Anderson Cancer Center (53)  ·  National Cancer Institute (NCI) (49)  ·  Novartis Pharmaceuticals (18)  ·  Celgene (17)  ·  Fred Hutchinson Cancer Center (14)  ·  Gilead Sciences (14)  ·  AbbVie (13)  ·  Amgen (12)  ·  Masonic Cancer Center, University of Minnesota (12)  ·  Incyte Corporation (11)  ·  Washington University School of Medicine (11)  ·  GlaxoSmithKline (10)  ·  Northwestern University (9)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9)  ·  Bristol-Myers Squibb (8)

Countries

United States (735)  ·  Spain (89)  ·  France (76)  ·  Italy (57)  ·  Canada (54)  ·  Australia (52)  ·  Germany (52)  ·  United Kingdom (47)  ·  China (40)  ·  Netherlands (27)  ·  South Korea (26)  ·  Japan (25)  ·  Belgium (24)  ·  Israel (24)  ·  Poland (13)

Top investigators

Roger Strair, MD, PhD (4)  ·  Farhad Ravandi-Kashani, MD (3)

Results publications

PMID 34398557, PMID 23400739, PMID 31215818, PMID 31527168, PMID 33197925, PMID 35857660, PMID 36841672, PMID 17151364, PMID 18297527, PMID 18550886, PMID 19010875, PMID 19029442, PMID 19139736, PMID 19503090, PMID 19840322, PMID 20117846, PMID 20460644, PMID 20563869, PMID 20644039, PMID 20732454, PMID 20797926, PMID 20936416, PMID 21145590, PMID 21494838, PMID 22080439, PMID 22080968, PMID 22448921, PMID 22987312, PMID 23092873, PMID 23233571, PMID 23256542, PMID 23393050, PMID 23682558, PMID 23829485, PMID 23887852, PMID 23973010, PMID 24200998, PMID 24241210, PMID 24276047, PMID 24355079, PMID 24615776, PMID 24615777, PMID 24615778, PMID 25441108, PMID 25655379, PMID 25824692, PMID 26139427, PMID 26384354, PMID 26472751, PMID 26675348

NIH funding

2018 (16), 2017 (12), 2019 (12), 2023 (12), 2014 (8), 2016 (7), 2015 (6), U01CA076576 (6), P30CA015083 (5), P30CA016672 (5), P30CA015704 (4), P30CA072720 (4), 2008 (3), N01CM62203 (3), P01CA018029 (3)